- Home
- OABI vs PRME Comparison
OABI vs PRME Comparison
Compare OABI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- PRME
- Stock Information
- Founded
- OABI 2012
- PRME 2019
- Country
- OABI United States
- PRME United States
- Employees
- OABI N/A
- PRME N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- OABI Health Care
- PRME Health Care
- Exchange
- OABI Nasdaq
- PRME Nasdaq
- Market Cap
- OABI 198.2M
- PRME 191.7M
- IPO Year
- OABI N/A
- PRME 2022
- Fundamental
- Price
- OABI $2.18
- PRME $4.72
- Analyst Decision
- OABI Strong Buy
- PRME Buy
- Analyst Count
- OABI 3
- PRME 6
- Target Price
- OABI $7.00
- PRME $9.38
- AVG Volume (30 Days)
- OABI 854.4K
- PRME 4.6M
- Earning Date
- OABI 08-07-2025
- PRME 08-04-2025
- Dividend Yield
- OABI N/A
- PRME N/A
- EPS Growth
- OABI N/A
- PRME N/A
- EPS
- OABI N/A
- PRME N/A
- Revenue
- OABI $26,744,000.00
- PRME $3,846,000.00
- Revenue This Year
- OABI N/A
- PRME $104.12
- Revenue Next Year
- OABI $45.65
- PRME $196.78
- P/E Ratio
- OABI N/A
- PRME N/A
- Revenue Growth
- OABI 27.07
- PRME 550.76
- 52 Week Low
- OABI $1.22
- PRME $1.11
- 52 Week High
- OABI $4.96
- PRME $6.75
- Technical
- Relative Strength Index (RSI)
- OABI 72.48
- PRME 88.59
- Support Level
- OABI $1.79
- PRME $2.28
- Resistance Level
- OABI $1.73
- PRME $4.21
- Average True Range (ATR)
- OABI 0.11
- PRME 0.42
- MACD
- OABI 0.04
- PRME 0.22
- Stochastic Oscillator
- OABI 93.97
- PRME 96.69
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.